>
Penn State Law rocked by secret audio exposing dark DEI agenda…
The Nuclear Missile That Vladimir Putin Just Tested Could Destroy an Area the Size...
Half a Million Waiting in Libya To Invade Europe
US To Develop Small Modular Nuclear Reactors For Commercial Shipping
New York Mandates Kill Switch and Surveillance Software in Your 3D Printer ...
Cameco Sees As Many As 20 AP1000 Nuclear Reactors On The Horizon
His grandparents had heart disease.
At 11, Laurent Simons decided he wanted to fight aging.
Mayo Clinic's AI Can Detect Pancreatic Cancer up to 3 Years Before Diagnosis–When Treatment...
A multi-terrain robot from China is going viral, not because of raw speed or power...
The World's Biggest Fusion Reactor Just Hit A Milestone
Wow. Researchers just built an AI that can control your body...
Google Chrome silently installs a 4 GB AI model on your device without consent
The $5 Battery That Never Dies - Edison Buried This 100 Years Ago

The study's lead researcher, Dr. Robert Naviaux of the San Diego School of Medicine is an internationally known expert in human genetics, inborn errors of metabolism, metabolomics, and mitochondrial medicine. He is the discoverer of the cause of Alpers syndrome — the oldest Mendelian form of mitochondrial disease — and the developer of the first DNA test to diagnose it. Naviaux is, by far, one of the most qualified people in the world to conduct this study.
During his research, Naviaux noted the transformative results of the drug suramin which was first developed in 1916 and used as an anti-parasitic drug for treating African sleeping sickness and river blindness. After giving a single dose of suramin to boys with autism, between the ages of five and 14, Naviaux recorded something incredible — their symptoms were significantly alleviated.
"After the single dose, it was almost like a roadblock had been released," he said. "If the future studies show that there's continued health benefits, this could be a game-changer for families with autism."